Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Genome-wide association study reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Volunteer first responders for out-of-hospital cardiac arrest at home: the missing link for improved survival?

    Publikation: Bidrag til tidsskriftLederForskningpeer review

  3. Risk of sports-related sudden cardiac death in women

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. New insights into the genetic etiology of Alzheimer's disease and related dementias

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Plasma high-density lipoprotein cholesterol and risk of dementia: observational and genetic studies

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Risk and impact of chronic cough in obese individuals from the general population

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Epigenetic regulation of F2RL3 associates with myocardial infarction and latelet function

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: We tested the hypothesis that the contrasting results for the effect of high-dose, purified omega-3 fatty acids on the prevention of atherosclerotic cardiovascular disease (ASCVD) in two randomized trials, Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) vs. Long-Term Outcomes Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridaemia (STRENGTH), can be explained by differences in the effect of active and comparator oils on lipid traits and C-reactive protein.

METHODS AND RESULTS: In the Copenhagen General Population Study (CGPS) with 106 088 individuals, to mimic trial designs we analysed those who met key inclusion criteria in REDUCE-IT (n = 5684; ASCVD = 852) and STRENGTH (n = 6862; ASCVD = 697). Atherosclerotic cardiovascular disease incidence was followed for the median durations of REDUCE-IT and STRENGTH (4.9 and 3.5 years), respectively. When combining changes in plasma triglycerides, low-density lipoprotein cholesterol, and C-reactive protein observed in the active oil groups of the original studies, estimated hazard ratios for ASCVD in the CGPS were 0.96 [95% confidence interval 0.93-0.99] mimicking REDUCE-IT and 0.94 (0.91-0.98) mimicking STRENGTH. In the comparator oil groups, corresponding hazard ratios were 1.07 (1.04-1.10) and 0.99 (0.98-0.99). Combining these results, the active oil vs. comparator oil hazard ratio was 0.88 (0.84-0.93) in the CGPS mimicking REDUCE-IT compared to 0.75 (0.68-0.83) in the REDUCE-IT. The corresponding hazard ratio was 0.96 (0.93-0.99) in the CGPS mimicking STRENGTH compared to 0.99 (0.90-1.09) in STRENGTH.

CONCLUSION: The contrasting results of REDUCE-IT vs. STRENGTH can partly be explained by a difference in the effect of comparator oils (mineral vs. corn), but not of active oils [eicosapentaenoic acid (EPA) vs. EPA + docosahexaenoic acid], on lipid traits and C-reactive protein. The unexplained additional 13% risk reduction in REDUCE-IT likely is through other effects of EPA or mineral oil.

OriginalsprogEngelsk
TidsskriftEuropean Heart Journal
Vol/bind42
Udgave nummer47
Sider (fra-til)4807-4817
Antal sider11
ISSN0195-668X
DOI
StatusUdgivet - 14 dec. 2021

Bibliografisk note

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

ID: 71680552